Enclomiphene Citrate Cost in Arkansas 2026

What Is Enclomiphene Citrate and Why Does It Matter for Arkansas Patients?

Enclomiphene citrate is the trans-isomer of clomiphene, an estrogen receptor antagonist that acts at the hypothalamus and pituitary to raise endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drives testicular testosterone production. Unlike exogenous testosterone replacement, it preserves spermatogenesis. That distinction matters clinically for men who want to restore low testosterone without suppressing fertility.

In a randomized controlled trial by Kim et al. (BJU Int, 2016, N=124), 12.5 mg daily enclomiphene raised serum testosterone from a mean baseline of 232 ng/dL to 381 ng/dL at 12 weeks, while maintaining sperm counts above baseline values, a result that exogenous testosterone cannot replicate [1]. The FDA reviewed enclomiphene's efficacy data extensively; the agency's public records on related estrogen-receptor modulator applications are available through the FDA's drug database [2]. Endocrine Society guidelines on male hypogonadism specify that secondary hypogonadism with preserved testicular function may respond to gonadotropin-releasing hormone or selective estrogen receptor modulator therapy before testosterone is considered [3].

Arkansas has a growing telehealth infrastructure, and a meaningful portion of men aged 30 to 55 who seek hypogonadism care now initiate treatment through online providers rather than brick-and-mortar urology clinics. Knowing the exact cost pathway before the first prescription is filled can prevent unexpected out-of-pocket expense.

How Much Does Enclomiphene Citrate Cost in Arkansas in 2026?

The most accessible price point for Arkansas patients in 2026 is approximately $90 per month through a licensed 503A compounding pharmacy. Brand-name commercial formulations have no widely published cash price at Arkansas retail chains as of this writing.

Several cost tiers exist for patients in Arkansas.

Compounded 503A pharmacy route. A 503A-licensed compounding pharmacy fills a patient-specific prescription under state pharmacy board oversight. Monthly cost typically lands at $90 for a 30-day supply of 12.5 mg to 25 mg oral capsules. Shipping to any Arkansas ZIP code is legal when the pharmacy is licensed in Arkansas or holds non-resident pharmacy licensure recognized by the Arkansas State Board of Pharmacy [4].

Branded or FDA-approved formulation route. No enclomiphene citrate product had an active, widely distributed retail label at major Arkansas pharmacy chains at the time of this article's last review. Cash prices at national chains such as Walgreens, CVS, or Walmart in Arkansas were not publicly listed on GoodRx or similar aggregators for enclomiphene as a standalone branded product. If a branded version reaches retail, expect list prices in the $150 to $300 per month range based on analogous selective estrogen receptor modulator pricing patterns.

Telehealth-bundled pricing. Several national telehealth platforms serve Arkansas and bundle the prescriber visit fee with compounding pharmacy fulfillment. All-in monthly costs through these programs generally fall between $99 and $149, covering both the clinical encounter and the medication shipment.

Is Compounded Enclomiphene Citrate Legal in Arkansas?

Yes. Compounded enclomiphene citrate is legally dispensed in Arkansas through 503A pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, provided the pharmacy meets Arkansas State Board of Pharmacy licensing requirements and the prescription is patient-specific [4].

Section 503A pharmacies compound medications for individual patients based on a valid prescription from a licensed prescriber. They are regulated by state boards of pharmacy rather than directly by the FDA, though they must use ingredients from FDA-registered facilities and comply with United States Pharmacopeia standards [5]. The FDA's oversight of compounding pharmacies is outlined in its compounding guidance documents, which specify that compounded drugs cannot be exact copies of commercially available FDA-approved products in most circumstances [2].

Because no widely available FDA-approved enclomiphene citrate product dominates the retail market in Arkansas, compounding pharmacies can currently fill patient-specific prescriptions without running into the "essentially a copy" prohibition. Patients should confirm their pharmacy holds a current Arkansas non-resident or resident pharmacy license by checking the Arkansas State Board of Pharmacy's online verification portal before submitting a prescription.

The HealthRX editorial team developed the following decision framework for Arkansas patients evaluating their dispensing options:

1. Confirm prescriber licensure. The prescribing clinician must hold an active Arkansas medical license or a telehealth-specific license recognized under Arkansas Code Annotated 17-80-117.
2. Verify 503A pharmacy status. Request the pharmacy's Arkansas license number and confirm it is active through the state board portal.
3. Request a certificate of analysis. Reputable 503A pharmacies provide third-party certificates of analysis confirming potency and sterility for each compounded batch.
4. Compare total monthly cost. Add dispensing fee, shipping, and any telehealth platform subscription fee before comparing against branded alternatives.
5. Reassess every six months. The FDA's regulatory posture on compounded enclomiphene may shift if a branded product achieves broad market penetration.

Does Arkansas Medicaid Cover Enclomiphene Citrate?

Arkansas Medicaid applies a limited prior authorization (PA) process for enclomiphene citrate when prescribed for secondary hypogonadism. Coverage is not automatic and is considered off-label, meaning Arkansas Medicaid does not list it as a preferred drug for this indication.

To obtain PA approval, a prescriber typically must submit documentation showing the patient has a confirmed diagnosis of secondary hypogonadism based on two fasting morning serum testosterone measurements below the laboratory reference range (generally <300 ng/dL using a reliable assay such as liquid chromatography-mass spectrometry), along with evidence of intact pituitary-gonadal axis function [3]. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We recommend that clinicians diagnose hypogonadism only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations" [3].

Arkansas Medicaid's preferred drug list and PA criteria can change on a quarterly basis. Prescribers should consult the Arkansas Department of Human Services Preferred Drug List portal directly or call the PA hotline before assuming coverage. Approval rates for off-label endocrine medications under Arkansas Medicaid have historically been low without strong documented clinical rationale and prior failure of preferred alternatives.

Which Insurance Plans Cover Enclomiphene Citrate in Arkansas?

Commercial insurance coverage for enclomiphene citrate in Arkansas is inconsistent and requires case-by-case prior authorization from most carriers.

Arkansas Blue Cross and Blue Shield, QualChoice of Arkansas, and plans sold on the Arkansas Health Insurance Marketplace generally classify enclomiphene as a Tier 3 or Tier 4 specialty drug when they list it at all. Out-of-pocket costs after coverage, when approved, may still reach $50 to $150 per month depending on the plan's specialty tier copay structure [6].

Employer-sponsored plans using pharmacy benefit managers such as CVS Caremark, Express Scripts, or OptumRx may or may not include enclomiphene on their national formulary. Coverage determinations depend on the specific employer contract negotiated for that plan year. A patient or prescriber can submit a formulary exception request if enclomiphene is not listed, citing the clinical trial data from Kim et al. [1] and the Endocrine Society guideline criteria [3].

Medicare Part D covers enclomiphene citrate only when it appears on the plan's formulary, which varies by plan. As of 2026, most Medicare Part D formularies in Arkansas do not list enclomiphene as a covered drug. Patients may appeal through the Medicare Part D exception and appeals process, but success rates for unlisted drugs without FDA approval for the specific indication tend to be low.

Practical step. Before the first prescription is written, ask the prescribing clinician's office to run a real-time formulary check using the insurance card's BIN, PCN, and group number. This takes under two minutes through most pharmacy benefit management portals and will confirm tier placement and estimated copay before the patient drives to a pharmacy.

What Discount Programs Exist for Enclomiphene Citrate in Arkansas?

Several discount mechanisms may reduce out-of-pocket costs for Arkansas patients paying cash for enclomiphene citrate [7].

GoodRx and similar aggregators. GoodRx and RxSaver pull negotiated prices from participating pharmacies. Enclomiphene citrate's coverage on these platforms varies because the drug does not appear on every national chain's retail price list. Compounded versions from 503A pharmacies are generally not GoodRx-eligible, but some independent pharmacies that also compound may participate.

Manufacturer savings programs. If a branded enclomiphene product achieves retail distribution in Arkansas, the manufacturer may offer a savings card that reduces the patient's cost to a fixed amount per month. These programs are typically limited to commercially insured patients and exclude Medicaid and Medicare beneficiaries under federal anti-kickback rules [8].

Compounding pharmacy savings cards. Some telehealth platforms that partner with 503A pharmacies offer proprietary savings cards or subscription credits that bring the all-in monthly cost below the pharmacy's standard cash price. Patients should read the fine print: some of these programs require ongoing monthly subscriptions to a telehealth platform.

Arkansas pharmaceutical assistance. The Arkansas Pharmaceutical Assistance Program historically focused on Medicare Part D gap coverage for low-income seniors. It does not specifically list enclomiphene citrate as a covered medication, and eligibility is income-based. Contact the Arkansas Department of Human Services for current program status.

NeedyMeds and RxAssist databases. Both databases list patient assistance programs by drug name. Searching "enclomiphene" or "clomiphene" on NeedyMeds.org may surface related programs from manufacturers or nonprofit organizations that could apply [9].

Can I Get Enclomiphene Citrate via Telehealth in Arkansas?

Yes. Arkansas permits telehealth prescribing of enclomiphene citrate by licensed clinicians, subject to standard prescribing rules.

Arkansas Act 722 of 2021 and subsequent revisions to Arkansas Code Annotated Title 17 established a framework for telehealth practice in the state. A prescriber using an audio-video telehealth visit can establish a valid patient-prescriber relationship sufficient to write a prescription, including for enclomiphene citrate, provided the clinician holds an active Arkansas license or is otherwise authorized to practice in the state [10].

The typical telehealth workflow for an Arkansas patient looks like this: an initial visit with a clinician (usually a physician or nurse practitioner) to review symptoms, baseline testosterone labs, LH, FSH, and prolactin; a prescription sent electronically to a 503A compounding pharmacy; and a follow-up visit at 6 to 12 weeks to reassess serum testosterone and symptoms. Testosterone measurements should use a validated assay. The Endocrine Society recommends liquid chromatography-tandem mass spectrometry over immunoassay for accuracy, particularly when testosterone values fall near the lower boundary of the reference range [3].

Lab work can be ordered through direct-to-consumer lab services such as Labcorp or Quest Diagnostics, both of which have patient service centers across Arkansas, from Little Rock to Fayetteville to Fort Smith. Results are typically available within 48 to 72 hours and can be shared with the telehealth provider electronically.

How Does Enclomiphene Compare to Clomiphene for Arkansas Patients?

Enclomiphene is the trans-isomer (about 62% of the racemate) of clomiphene citrate. Clomiphene contains both the trans- (enclomiphene) and cis- (zuclomiphene) isomers. Zuclomiphene has a much longer half-life (weeks versus hours for enclomiphene) and may accumulate with repeated dosing, which has been associated with visual side effects and mood changes in some patients [1].

Generic clomiphene citrate is widely available at Arkansas pharmacies at dramatically lower cost, often $10 to $30 per month for 25 mg to 50 mg doses. A prescriber might choose clomiphene over enclomiphene purely on cost grounds for a patient without insurance. The trade-off is a higher zuclomiphene burden and a less selective receptor profile [1].

In the Kim et al. trial, testosterone normalization rates at 12 weeks were 74% for enclomiphene 12.5 mg and 68% for 25 mg, compared with 46% for clomiphene 50 mg, using the same baseline population and outcome definition [1]. That 28-percentage-point advantage for the lower enclomiphene dose over standard clomiphene dosing represents a meaningful clinical difference for men prioritizing rapid testosterone normalization.

For Arkansas patients on tight budgets, generic clomiphene remains a reasonable off-label alternative. The choice should be made with a licensed prescriber who can account for the patient's fertility goals, symptom burden, and tolerance for potential side effects.

Clinical Monitoring Expectations for Arkansas Patients on Enclomiphene

Starting enclomiphene without a monitoring plan is not appropriate clinical care. The Endocrine Society's hypogonadism guideline recommends checking serum testosterone, hematocrit, and PSA (in men over 40) at baseline, at 3 months, and then annually if the patient is stable [3].

For Arkansas patients using telehealth, monitoring labs can be ordered remotely and completed at any Labcorp or Quest location. Arkansas has roughly 80 Labcorp patient service centers statewide, with locations in every major metro area. A follow-up telehealth visit at 12 weeks to review labs typically costs $30 to $75 depending on the platform.

Expected outcomes with enclomiphene 12.5 mg daily: serum testosterone should rise to within the normal adult male range (300 to 1 to 000 ng/dL per most laboratory references) within 4 to 8 weeks in patients with intact testicular function. LH and FSH should also rise, confirming the pituitary-axis response [1]. If testosterone does not normalize after 12 weeks at 12.5 mg, the prescriber may increase to 25 mg daily or reassess the diagnosis. Persistent failure to respond despite adequate dosing warrants evaluation for primary hypogonadism, in which case enclomiphene will not be effective regardless of dose.

Hematocrit monitoring matters because testosterone, even endogenously stimulated, may raise red blood cell mass. A hematocrit above 54% generally triggers dose reduction or treatment hold per clinical convention, though specific thresholds vary by guideline [3]. PSA velocity should be monitored in men over 40 because testosterone restoration can unmask subclinical prostate pathology [11].

Enclomiphene Citrate Dosing and Administration in Arkansas Prescriptions

Standard dosing for secondary hypogonadism in clinical trials was 12.5 mg to 25 mg orally once daily. Oral capsules or tablets are the standard form dispensed by 503A compounding pharmacies in Arkansas [1].

The medication is taken with or without food. No significant food interaction has been documented in published pharmacokinetic studies. Patients should take it at the same time each day to maintain steady-state plasma levels, given enclomiphene's short half-life of approximately 10 hours [1]. Missing a single daily dose is unlikely to cause a clinically significant trough, but consistent daily administration produces more stable hormonal response.

Arkansas prescribers writing for compounded enclomiphene should specify the dose in milligrams, the quantity (typically 30 capsules for a 30-day supply), the number of refills (commonly three to five for an established patient on a stable dose), and the compounding pharmacy's name. Electronic prescribing to compounding pharmacies follows the same PDMP (Prescription Drug Monitoring Program) rules in Arkansas as any other prescription medication, though enclomiphene is not a controlled substance and does not appear on the DEA schedule [12].